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Introduction
It has been over 10 y since the first HPV vaccines were licensed
and introduced in a number of countries around the world. As
only the second vaccine (after hepatitis B) that prevents an infec-
tion that can lead to the development of cancer, HPV vaccine
occupies an important position in our armamentarium of vac-
cines yet remains underutilized. The number of national HPV
vaccination programs has increased steadily; as of June 2017, 91
countries had introduced national HPV vaccination programs,1
with that number now over 100. Over the past 10+ y, several
modifications have been made to the vaccination regimen (e.g.,
moving from three to two doses if the first dose is administered
before age 15 y), in the type of vaccine available (e.g., introduction
of the 9-valent vaccine), and in the target of vaccination (e.g.,
many countries have shifted from female-only to gender-neutral
vaccination). There is great variability across the globe in terms of
HPV vaccination policies and accompanying barriers to the
implementation and/or sustainability of programs. It is well
known, for instance, that Japan’s initial success with vaccination
was undermined by several factors, leading to a precipitous drop
in vaccination rates, with little subsequent recovery.2 Other coun-
tries, such as the U.S.,3 have struggled to achieve vaccination goals,
and still others have faced setbacks but with good recovery (e.g.,
Denmark and Ireland).4,5 At the same time, many countries,
including China,6 still have not implemented national vaccination
programs, with the cost of vaccines presenting a significant obsta-
cle, particularly for those countries that are not eligible for reduced
pricing through Global Alliance for Vaccines and
Immunisation (GAVI) or other mechanisms. Other countries,
such as Malaysia, Rwanda, Australia, and the U.K., have achieved
sustained high levels of vaccination.7–10 Unwarranted fears about
HPV vaccine and the proliferation of misinformation, particularly
via social media, have proven to be significant and widespread
obstacles to achieving andmaintaining high vaccination rates.11,12
This special issue of Human Vaccines & Immunotherapeutics
brings together a number of timely articles covering several topic
areas related to HPV vaccination. Included among these are
papers focused on: social media and the Internet; vaccination
policy; interventions to improve vaccination rates; new domains
related to HPV vaccine knowledge, attitudes, and behaviors;
alternative settings for vaccine delivery; HPV prevalence,
incidence, and type distribution among specific populations;
HPV-related oropharyngeal cancers (OPC), vaccine character-
istics; and cost-effectiveness modeling. The 68 papers in this
special issue include research papers, reviews or policy pieces,
short reports, and commentaries.
Social media and the Internet
As noted above, social media have enabled the spread of false
information about HPV vaccination, presenting clinicians and
researchers with difficult challenges.13 At the same time, social
media also convey accurate information about vaccines and can
(and should) be used by clinicians and researchers to counter-
act the proliferation of false information. Included in this
special issue are several papers addressing social media and
online information about HPV immunization. These include
a systematic review examining how social media may affect
attitudes about, and uptake of, HPV vaccine,14 as well as several
research papers reporting on analyses of HPV-vaccine-related
posts on Instagram,15 Facebook,16 and Twitter.17,18 Two addi-
tional articles examine the readability of online information19
and present a content analysis of online continuing medical
education about HPV vaccination, respectively.20
HPV vaccination policy
The ways in which countries, regions, and states craft public
health policies about HPV vaccination have had an enormous
effect on the success or failure of vaccination programs. Five
articles in this special issue address varying aspects of policy. One
paper involves a unique examination of U.S. states’ statutes and
regulations regarding HPV vaccination by using WestlawNext,
a legal research database.21 A second paper points to the lower
vaccination rates in rural areas of the U.S. and suggests policy
strategies to improve vaccine uptake in these areas.22 A third
paper examines, in detail, policy challenges and issues with the
introduction of vaccines in China.6 Another paper addresses the
challenges associated with implementing effective HPV vaccina-
tion programs for men who have sex with men,23 and a final
paper reviews the arguments for and against the implementation
of policies to vaccinate female sex workers.24
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Interventions and pre-interventions to improve
vaccination rates
There is a great need to continue to develop and evaluate
interventions to increase HPV vaccination uptake. Eight arti-
cles in this special issue focus on pre-interventional and
interventional research to improve vaccine initiation and ser-
ies completion, including a review of technology-based inter-
ventions (e.g., text messaging and electronic health record
reminders) designed to improve vaccination rates.25 Three
papers involve evaluations of a patient navigator program,26
a quality improvement intervention,27 and a tablet-based tai-
lored messaging intervention,28 respectively, in terms of their
effects on vaccine initiation and series completion. An addi-
tional article reports on the acceptability to caregivers of the
patient navigator program.29 Another research report30 exam-
ines secondary outcomes from a previously reported multi-
component intervention designed to improve health-care
provider (HCP) communication about HPV vaccination.31
Still another paper evaluates vaccine-related community-
clinical linkages and addresses the implications for vaccine
intervention efforts.32 A final research study looks at the
effects on knowledge about HPV due to an educational inter-
vention targeted to undergraduate students in Italy.33
Knowledge, attitudes, and behaviors
There are 23 research reports, 2 review articles, and 1 commen-
tary addressing different aspects of HPV vaccine knowledge,
attitudes, and behaviors. An enormous amount of past research
has addressed knowledge and attitudes about HPV vaccination.
However, the articles in this special issue make some unique
contributions to the literature. One paper reports on a systematic
review of literature on the determinants of vaccine hesitancy in
Europe,34 and another offers practical guidance to HCPs in how
to refute HPV vaccine myths.35 Meanwhile, a commentary sum-
marizes consensus messages to strengthen parental confidence
in HPV vaccination that were generated at the U.S. National
HPV Vaccination Roundtable meetings.36 Other papers address
provider, parent, and patient issues specific to understudied
countries, such as China, India, and Italy, as well as areas of
vaccine hesitancy and/or low vaccination uptake in the U.S. and
Canada.37–44 Another research report found that few providers
in a U.S. regional health plan administered vaccine in a way that
was consistent with Healthcare Effectiveness Data and
Information Set benchmarks.45 Two articles explore issues of
trust among African American parents and how this impacts
vaccination.46,47 Two additional papers examine issues of risk
compensation post-vaccination in the U.S. and in China,
respectively.48,49 Still other articles involve a latent-class analysis
of parental worries,50 adolescents’ perspectives on vaccination,51
college students’ lack of awareness of HPV diseases and
vaccination,52 knowledge and attitudes of caregivers of child-
hood cancer survivors,53 HCPs’ recommendation profiles and
perceptions of barriers to vaccination,54,55 and perspectives on
vaccination among boys in Sweden.56 Finally, articles in this
section apply the Precaution Adoption Process Model to
a study of parental vaccine hesitancy,57 examine preferences
for a vaccine-related mobile health tool among young men
who have sex with men,58 and report on the association between
vaccination history in women and the HPV vaccine status of
their 11–14-y-old children.59
Alternative settings for HPV vaccine delivery
In countries like the U.S. that have not implemented school-
located HPV vaccination programs, efforts have been made to
expand promotion and/or delivery of vaccines beyond tradi-
tional pediatric or family practice office settings. Seven articles
in this special issue consider such alternative settings, with
papers addressing pharmacies and pharmacists as vaccine
providers60,61 and gynecological providers.62 Two articles
examine the potential role that dentists and dental practices
can play in promoting HPV vaccination,63,64 and one addi-
tional paper considers barrier and facilitators of vaccination at
school-based health centers.65 A final study in this section
used Veterans Affairs Medical Center data to identify missed
opportunities for vaccination among young adult men and
women who were military veterans.66
HPV prevalence, incidence, and type distribution –
implications for vaccination
Five articles in this special issue focus on HPV infection and
disease in specific populations, which has implications for HPV
vaccination programs. Two papers examine HPV genotype dis-
tribution among women in Changzhou,67 China and among
women with cervical cytological abnormalities in Xinjiang,
China, respectively.68 The Changzhou study found the most
prevalent types in women with cervical cancer to be 16, 52,
and 58. Similarly, the Xinjiang study identified types 16, 58,
and 52 as the most prevalent types. Of note, types 52 and 58
are not covered by the bivalent and quadrivalent vaccines, only
by the nonavalent vaccine. Another article looks at genital HPV
prevalence among adult immigrants living in the U.S., finding
that high-risk HPV prevalence was lower among this population
compared to those born in the U.S.69 An addition paper evalu-
ated incident genital HPV infections in adult women living with
HIV/AIDS, reporting that 35% of incident infections could have
been prevented by the 9-valent vaccine.70 A final article exam-
ined the hypothesis that obesity status might be associated with
greater risk of HPV infection in the anal canal due to an
increased associated risk of micro and macro tears in the
epithelium.71 Results were mixed but certainly support universal
gender-neutral HPV vaccination.
Oropharyngeal HPV
The incidence of HPV-related OPC has increased significantly
over the last 15 y in the U.S. and in other high-income
countries, particularly among men.72 Although HPV vaccines
are not yet indicated for the prevention of HPV-related OPC,
there is indirect evidence that vaccination may be effective.73–
75 Three articles address aspects of HPV-related OPC. One
paper reviews the epidemiology of OPC, as well as approaches
to prevention and emerging technologies for screening.76 In
a commentary, there is a discussion of the roles that otolar-
yngologists can play in promoting vaccination.77 A final study
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examined whether sex differences in immune response may
explain the significantly lower incidence of OPCs among
women compared to men.78
Other topics related to HPV and HPV vaccination
Seven articles in this special issue cover a variety of key issues
central to HPV vaccination. One reports on the impact of
updated medical costs on cost-effectiveness estimates for HPV
vaccination in the U.S.,79 while another estimates the epidemio-
logical impact and cost-effectiveness of the 9-valent vaccine in
Spain.80 An additional paper finds evidence for cross-protection,
but no evidence for type replacement 11 y after the introduction
of HPV vaccine in the U.S.81 A study involving a 10-y follow-up
of 10–14-y-old girls vaccinated with the bivalent vaccine found
strong sustained antibody levels, with no severe adverse events
attributable to the vaccine.82 Another report looked at the effect
of long intervals between doses of HPV vaccine on immune
response, finding that intervals of several years do not negatively
impact the immune response to the second dose.83 Also in this
section, there is an article involving evaluation of the feasibility
of using a combined approach to HPV vaccination and screen-
ing (also known as FASTER) inMexico.84 The final article in this
section reports on the important effort to overcome barriers to
implementation in low- and middle-income countries related to
the need for continuous refrigeration during transport. Using
a mouse model, they show immunogenicity and protective effi-
cacy of the 9-valent vaccine after it had undergone a spray drying
and stabilizing process.85
Conclusions
Despite the availability of HPV vaccine in many locales for
over 10 y, there remain substantial barriers to adequate cover-
age in many countries and regions. Reasons for poor rates of
vaccination include attitudinal and behavioral barriers, system
barriers, logistical challenges, and political and policy barriers.
The 68 papers in this issue reflect the richness and diversity of
research and thinking around HPV vaccination. Our hope is
that the kind of work represented here will help in the global
effort to move the dial on HPV vaccination to increased
utilization of this very important disease-prevention method
so that future suffering and deaths from HPV-related diseases
can be minimized and the goal of HPV-cancer elimination
can eventually become a reality.
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